Fortrea Holdings Inc. (FTRE) Stock Price & Analysis
Fortrea Holdings Inc. (FTRE) rose 0.10% to USD 19.52 as of July 26, 2026 at 10:24 UTC, according to Nexqual real-time market data.
FTRE last closed at USD 19.5; the session ranged USD 19.25–20.09 on volume of 1,342,962 shares. Market capitalization is $1.85B, with a 52-week range of USD 5.27–20.19 (NMS). Source: Nexqual, July 26, 2026 at 10:24 UTC.
Key Statistics (as of July 26, 2026 at 10:24 UTC)
| Price | USD 19.52 |
|---|---|
| Change | ▲ 0.10% (up) |
| Previous Close | USD 19.5 |
| Open | USD 19.77 |
| Day Range | USD 19.25 – 20.09 |
| 52-Week Range | USD 5.27 – 20.19 |
| Volume | 1,342,962 shares |
| Market Cap | $1.85B |
| Exchange | NMS |
Technical Analysis (FTRE)
Nexqual's technical model rates FTRE "BUY" based on 5 bullish and 3 bearish signals across 125 daily candles, as of July 26, 2026 at 10:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.21 (overbought) |
| vs SMA50 | Above (USD 16.36) |
| MACD | 0.73 (positive) |
Analyst Ratings (FTRE)
Wall Street analysts rate FTRE "Buy" based on 11 analysts, with a mean price target of USD 17.25 (range USD 11–20), per Nexqual as of July 26, 2026 at 10:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 17.25 |
| High Target | USD 20 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 5 / 5 / 2 |
Earnings (FTRE)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.18 |
| Revenue Estimate | $647.59M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.16 vs est 0.05 ▲ beat |
| 2025-12-31 | USD 0.09 vs est 0.16 ▼ miss |
| 2025-09-30 | USD 0.12 vs est 0.16 ▼ miss |
| 2025-06-30 | USD 0.19 vs est 0.08 ▲ beat |
Source: Nexqual, July 26, 2026 at 10:24 UTC.
Financials & Fundamentals (FTRE)
| Total Revenue | $2.71B |
|---|---|
| Revenue Growth (YoY) | -2.30% |
| Gross Margin | +18.86% |
| Operating Margin | +0.52% |
| Profit Margin | -16.50% |
| ROE | -64.55% |
| Debt / Equity | 212.7 |
| Current Ratio | 0.95 |
| Total Cash | $147.50M |
| Total Debt | $1.12B |
| Free Cash Flow | $285.61M |
Source: Nexqual, July 26, 2026 at 10:24 UTC.
Financial Health Score (FTRE)
Nexqual rates Fortrea Holdings Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 10:24 UTC.
| Growth | Mixed — Revenue +1.0% YoY (annual), slow |
|---|---|
| Profitability | Weak — Gross margin 19%, operating 1% |
| Balance Sheet | Critical — $148M cash vs $1.12B debt |
| Cash Flow | Solid — FCF $286M, 10% margin |
| Efficiency | Critical — ROE -65%, ROA -0.1% |
Ownership (FTRE)
| Insider Ownership | +1.01% |
|---|---|
| Institutional Ownership | +110.80% |
| Shares Outstanding | 94.58M |
| Float | 93.71M |
| Short % of Float | +12.75% |
Source: Nexqual, July 26, 2026 at 10:24 UTC.
Leadership (FTRE)
Fortrea Holdings Inc. is led by Anshul Thakral (age 47), CEO & Director, per Nexqual as of July 26, 2026 at 10:24 UTC.
| CEO & Director | Anshul Thakral (age 47) |
|---|---|
| COO & President of Clinical Services | Mark A. Morais (age 48) |
Major Backers & Investors (FTRE)
Notable institutional backers of Fortrea Holdings Inc. include Goldman Sachs, Corvex Management LP, Sessa Capital IM, L.P., according to Nexqual as of July 26, 2026 at 10:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Goldman Sachs | 8.56% |
| Corvex Management LP | 4.91% |
| Sessa Capital IM, L.P. | 4.86% |
| Fidelity | 3.56% |
| AQR Capital Management, LLC | 3.49% |
| Charles Schwab Investment Management, Inc. | 3.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.3% |
| Vanguard Group | 13.47% |
| State Street | 4.34% |
| Deutsche Bank AG | 2.72% |
Source: Nexqual, July 26, 2026 at 10:24 UTC.
From Fortrea Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property In the course of conducting our business, we have developed, and continue to develop and use, proprietary software, systems, processes, databases and other intellectual property.
- We seek to protect our proprietary and confidential information and trade secrets through confidentiality agreements with employees, customers, and other third parties, as well as through administrative and technical safeguards.
- We believe our broad customer base positions us at the forefront of innovation in healthcare and allows us to help our customers efficiently bring the best therapeutic solutions to patients.
- Our integrated clinical pharmacology solution supports the increasing complexity in early phase trials with precision, quality and safety.
Partnerships
- On March 9, 2024, the Company, together with its wholly-owned subsidiary, Fortrea Inc., entered into an Asset Purchase Agreement (the "Purchase Agreement") with Endeavor Buyer LLC, an affiliate of Arsenal Capital Partners, to sell the operations of Fortrea Patient Access Inc. and its subsidiaries and Endpoint Clinical, Inc. and its subsidiaries; which are all collectively referred to as the Enabling Services Segment.
- The insights gathered show consistent alignment with industry benchmarks and demonstrate meaningful progress across key engagement drivers, including collaboration, inclusion, and confidence in leadership.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | USD 52.95 | ▲ 0.19% |
| NUVL | Nuvalent, Inc. | USD 123.96 | ▲ 0% |
| APGE | Apogee Therapeutics, Inc. | USD 134.28 | ▲ 0.15% |
| VSTS | Vestis Corporation | USD 15.58 | ▼ 2.01% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 10:24 UTC. This page is informational and not investment advice.